Photo by Pixabay on Pexels.com
KUALA LUMPUR — MBSB Research has maintained a POSITIVE outlook on the healthcare sector following strong 4QFY25 earnings in the US and Europe, driven largely by pharmaceuticals. Demand for GLP-1 drugs, used in diabetes and obesity treatment, lifted pharmaceutical performance, while US hospitals reported resilient inpatient volumes despite labour shortages.
Medical devices and equipment also saw higher demand for high-margin treatments, with oncology drugs adding further momentum. Malaysian healthcare players are expected to mirror global trends, supported by medical tourism, government initiatives to reduce medical costs, recovery in the glove sector, and growth in the halal pharmaceutical market. These factors provide additional upside, positioning Malaysia’s healthcare industry for sustained expansion in 2026.
Read More News on Latest Malaysia
Read More News on Business News Malaysia
Read More News on SG Business News
Read More News on World Future TV
Sepang International Circuit may host a Formula One race with Bahrain potentially funding costs, reviving…
Overland pipelines help bypass Gulf blockades, but shipping delays and rising costs continue to strain…
Malaysia and Russia deepen diplomatic ties ahead of their 60th anniversary, enhancing collaboration in trade,…
The FBM KLCI is expected to remain cautious this week as investors monitor the US…
Malaysia's stock market shows resilience, supported by strong domestic growth amid global uncertainties, analysts advise…
Malaysia is reviewing its petroleum reserves to enhance energy security and address global supply uncertainties…
This website uses cookies.